{
    "title": "MuTaTo vs Cancer",
    "inventor_name": "Ilan Morad",
    "publication_year": 2018,
    "device_name": "MuTaTo",
    "goal": "Rapid cure of cancer using a multi-target toxin composed of several tumor-binding peptides linked to a cytotoxic toxin.",
    "problem_addressed": "Cancer treatment resistance due to single-target drugs and tumor heterogeneity; need for a therapy that can kill cancer cells despite mutations and drug efflux.",
    "concept_summary": "MuTaTo is a construct that combines two or more peptide ligands, each binding a different extracellular tumor antigen, with a potent toxin. The multi-peptide targeting reduces the chance that cancer cells can escape by mutating a single receptor, while the toxin provides rapid cytotoxicity. The construct is produced using phage-display-derived peptides and can be covalently linked directly or via an organic scaffold/carrier.",
    "detailed_description": "The invention describes constructs comprising at least two different peptides that bind distinct extracellular tumor antigens (e.g., EGFR, PD-L1, HER2, etc.) and at least one toxin (e.g., diphtheria toxin, Pseudomonas exotoxin, ribosome-inactivating proteins). Peptides and toxins may be repeated multiple times on a scaffold, and the whole assembly can be covalently linked directly or through a carrier. The multi-target approach is claimed to produce synergistic cytotoxic effects and to be less susceptible to resistance mechanisms such as receptor loss or drug efflux.",
    "principles": [
        "Multi-target peptide binding",
        "Toxin-mediated cytotoxicity",
        "Phage-display peptide selection",
        "Covalent conjugation of peptides and toxins"
    ],
    "scientific_domains": [
        "Molecular Biology",
        "Biochemistry",
        "Pharmacology",
        "Oncology"
    ],
    "mechanisms_of_action": [
        "Peptide ligands bind distinct extracellular tumor antigens on cancer cells",
        "Covalently attached toxin is internalized and kills the cell",
        "Synergistic effect from simultaneous targeting of multiple receptors reduces chance of escape mutations"
    ],
    "materials": [
        "Peptide",
        "Protein toxin",
        "Organic scaffold",
        "Carrier molecule"
    ],
    "energy_sources": [],
    "inputs": [
        "Synthetic peptide-toxin constructs",
        "Cancer cells expressing target antigens"
    ],
    "outputs": [
        "Cancer cell death",
        "Therapeutic effect (tumor regression)"
    ],
    "claimed_performance": "Effective from day one, lasting a few weeks, minimal side-effects, and a one-dose rapid cure of cancer.",
    "experimental_evidence": null,
    "replication_status": null,
    "keywords": [
        "MuTaTo",
        "multi-target toxin",
        "peptide therapy",
        "cancer cure",
        "phage display",
        "targeted toxin"
    ],
    "related_technologies": [
        "Antibody-drug conjugates",
        "Bispecific antibodies",
        "Targeted toxin therapy"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.7,
    "practicability_score": 0.6,
    "fringe_score": 0.4,
    "evidence_strength": 0.3,
    "risk_score": 0.5,
    "trl_estimate": 4,
    "source_urls": [
        "https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939",
        "WO2018061004A1.pdf"
    ],
    "organizations": [
        "Accelerated Evolution Biotechnologies Ltd. (AEBi)",
        "AEBi"
    ],
    "applications": [
        "Cancer treatment"
    ],
    "limitations": [
        "No peer-reviewed clinical data presented",
        "Potential immunogenicity of peptide-toxin constructs",
        "Manufacturing complexity of multi-peptide scaffolds"
    ],
    "open_questions": [
        "Efficacy and safety in human patients",
        "Pharmacokinetics and biodistribution of the constructs",
        "Scalability and cost of production"
    ],
    "red_flags": [
        "Extraordinary claim of a one-dose cure without published trial results",
        "Lack of quantitative efficacy data",
        "Potential hype in media coverage"
    ],
    "evidence_quotes": [
        "Our results are consistent and repeatable.",
        "MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically.",
        "By using at least three targeting peptides on the same structure with a strong toxin, we made sure that the treatment will not be affected by mutations.",
        "The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used.",
        "When the toxin is strong, it has a high probability of killing the cancer cell before detoxification occurs."
    ],
    "category": "Medical & Dental Technologies"
}